Press release
The non-infectious uveitis market is expected to reach USD 1.45 billion by 2034, with AbbVie and Novartis as major players
non-infectious uveitis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72679
With rising prevalence of autoimmune conditions such as rheumatoid arthritis, ankylosing spondylitis, and Behçet's disease, demand for effective therapies for NIU has grown significantly. Recent advances in biologics and targeted therapies are redefining treatment options, making the non-infectious uveitis market a dynamic and fast-growing segment of the ophthalmology space.
Market Overview
• Market Size 2024: USD 0.65 billion
• Forecast 2034: USD 1.45 billion
• CAGR (2024-2034): 8.2%
Key Highlights:
• Increasing prevalence of autoimmune diseases is driving the NIU treatment market.
• Biologic therapies such as anti-TNF agents are revolutionizing treatment approaches.
• Rising awareness and earlier diagnosis of uveitis contribute to market growth.
• Strategic collaborations between biotech firms and pharmaceutical companies are accelerating drug development.
Challenges include treatment side effects, high therapy costs, and limited availability of ophthalmology specialists in certain regions. Nevertheless, innovation in biologics and drug delivery systems is shaping a promising future.
Market Segmentation
By Treatment Type
• Corticosteroids (Topical, Oral, Injectable, Implantable)
• Immunosuppressive Agents
• Biologic Therapies (Anti-TNF, Interleukin Inhibitors, Others)
• Targeted Small Molecules
• Combination Therapies
By Route of Administration
• Oral
• Intravenous (IV)
• Intravitreal
• Subcutaneous
• Others
By Disease Type
• Anterior Uveitis
• Intermediate Uveitis
• Posterior Uveitis
• Panuveitis
By End User
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers
• Research Institutes
Segmentation Summary:
Corticosteroids remain the first-line treatment, but biologics are expected to grow fastest due to their targeted action and long-term efficacy. Posterior uveitis and panuveitis represent the most severe forms and account for significant demand. Hospitals and specialty ophthalmic clinics are the primary end users, reflecting the need for expert care and advanced facilities.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72679/non-infectious-uveitis-market
Regional Analysis
North America
• Largest market in 2024, with ~40% share.
• Growth driven by high prevalence of autoimmune diseases and advanced healthcare infrastructure.
• The U.S. leads due to strong R&D pipelines and biologics adoption.
Europe
• Significant market share supported by government funding and growing awareness.
• Germany, France, and the UK lead in terms of treatment access and clinical trials.
• EMA's regulatory support for orphan and biologic drugs strengthens adoption.
Asia-Pacific
• Fastest-growing region, CAGR above 9.5%.
• Rising cases of autoimmune disorders and increasing ophthalmic disease burden in China and India.
• Expanding healthcare infrastructure and affordability improvements boost access.
Middle East & Africa
• Early adoption stage, with increasing investments in healthcare facilities.
• Growing partnerships with global pharma firms for drug access.
Latin America
• Brazil and Mexico drive regional demand with expanding ophthalmology care facilities.
• Adoption is moderate but improving with growing access to biologics.
Regional Summary:
While North America and Europe dominate due to established systems and biologics availability, Asia-Pacific is expected to be the fastest-growing market by 2034, fueled by its large patient pool and improving healthcare infrastructure.
Market Dynamics
Growth Drivers
• Rising Autoimmune Disease Prevalence: Increasing cases of rheumatoid arthritis and Behçet's disease drive NIU demand.
• Biologic Therapies: Anti-TNF and IL inhibitors are transforming treatment with higher efficacy and reduced relapses.
• Advancements in Drug Delivery: Intravitreal implants and sustained-release formulations improve compliance.
• Awareness & Early Diagnosis: Better screening and patient education accelerate treatment initiation.
Key Challenges
• High Therapy Costs: Biologics and targeted therapies remain expensive, limiting access in low-income regions.
• Side Effects: Long-term use of corticosteroids and immunosuppressants may cause complications.
• Regulatory Barriers: Stringent approval processes for ophthalmology drugs may delay launches.
Latest Trends
• Shift Toward Targeted Therapies: Personalized medicine and biologics leading future pipelines.
• Sustained-release Implants: Reducing dosing frequency and improving patient outcomes.
• Clinical Trials in Rare Diseases: Focus on NIU associated with rare autoimmune conditions.
• Digital Ophthalmology: Teleophthalmology and digital monitoring enhancing patient follow-up.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72679
Competitive Landscape
Key Players
• AbbVie Inc. (Humira, Rinvoq)
• Novartis AG (Beovu, Ilaris)
• Santen Pharmaceutical Co., Ltd.
• Bausch + Lomb Incorporated
• Regeneron Pharmaceuticals, Inc.
• Allergan (AbbVie)
• EyePoint Pharmaceuticals, Inc.
• Clearside Biomedical
• Roche Holding AG
• UCB Pharma
• Alimera Sciences, Inc.
• Ocular Therapeutix, Inc.
• Johnson & Johnson Vision Care, Inc.
• Pfizer Inc.
• Biogen Inc.
Competitive Summary:
The competitive landscape is dominated by companies investing in biologics and advanced delivery systems. AbbVie, Novartis, and Roche are leaders with strong pipelines in ophthalmology. Smaller firms like EyePoint and Clearside Biomedical focus on sustained-release implants, while collaborations and acquisitions remain central strategies to strengthen portfolios.
Conclusion
The Non-Infectious Uveitis Market is projected to grow from USD 0.65 billion in 2024 to USD 1.45 billion by 2034, expanding at a healthy CAGR of 8.2%. Rising autoimmune disease prevalence, biologic therapy adoption, and innovations in drug delivery systems are driving growth.
North America and Europe currently dominate, but Asia-Pacific will be the fastest-growing region, fueled by its large patient base and expanding healthcare investments.
Although challenges such as therapy costs and regulatory hurdles persist, advances in biologics, targeted therapies, and sustained-release devices will continue to transform patient outcomes. For pharmaceutical companies, biotech innovators, and investors, this market presents a strong opportunity in one of ophthalmology's most critical therapeutic areas.
This report is also available in the following languages : Japanese (非感染性ぶどう膜炎市場), Korean (비감염성 포도막염 시장), Chinese (非感染性葡萄膜炎市场), French (Marché de l'uvéite non infectieuse), German (Markt für nichtinfektiöse Uveitis), and Italian (Mercato dell'uveite non infettiva), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72679/non-infectious-uveitis-market#request-a-sample
Our More Reports:
Filtration Market
https://exactitudeconsultancy.com/reports/73516/filtration-market
Fermenters and Bioreactors Market
https://exactitudeconsultancy.com/reports/73517/fermenters-and-bioreactors-market
Organs-on-Chips Market
https://exactitudeconsultancy.com/reports/73518/organs-on-chips-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The non-infectious uveitis market is expected to reach USD 1.45 billion by 2034, with AbbVie and Novartis as major players here
News-ID: 4204247 • Views: …
More Releases from Exactitude Consultancy
Neuronal Ceroid Lipofuscinosis (NCL) Market to Reach USD 1.38 Billion by 2034, G …
Introduction
Neuronal Ceroid Lipofuscinosis (NCL), commonly referred to as Batten disease, is a group of rare, inherited neurodegenerative disorders that primarily affect children. Characterized by progressive vision loss, seizures, cognitive decline, and motor dysfunction, NCLs represent one of the most devastating categories of lysosomal storage disorders.
Until recently, treatment options were limited to symptomatic care. However, with advances in gene therapy, enzyme replacement therapy (ERT), and orphan drug development, the NCL market…
Cryptococcosis Market to Reach USD 9.8 Billion by 2034, Growing at 5.9% CAGR
Introduction
Cryptococcosis is a serious opportunistic fungal infection caused by Cryptococcus neoformans and Cryptococcus gattii. It primarily affects immunocompromised individuals, especially those with HIV/AIDS, organ transplant recipients, and patients undergoing immunosuppressive therapies. Despite being preventable and treatable, cryptococcosis continues to pose a significant global health burden, particularly in low- and middle-income countries where HIV prevalence is high.
Current treatment relies on antifungal agents such as amphotericin B, flucytosine, and fluconazole. However, limitations…
Key Players in the Tropomyosin Receptor Kinase (TRK) Fusion Cancer Market, Which …
Cancer research has entered a new era with the rise of precision medicine and genomic profiling. Among the most important breakthroughs is the identification of TRK (Tropomyosin Receptor Kinase) gene fusions, rare but actionable oncogenic drivers found in multiple solid tumors. These gene fusions, involving NTRK1, NTRK2, and NTRK3, lead to abnormal TRK protein signaling that fuels tumor growth.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72681
Targeted therapies for…
Glycan Analysis Market to Reach USD 1.36 Billion by 2034, Growing at 9.8% CAGR
Introduction
Glycan analysis is a critical tool in biotechnology and pharmaceuticals, enabling detailed study of carbohydrate structures (glycans) that play vital roles in protein folding, stability, and cell signaling. Glycans are central to understanding disease mechanisms, developing biologics, and ensuring product safety and efficacy in biopharmaceutical manufacturing.
With the rise of monoclonal antibodies, biosimilars, vaccines, and cell & gene therapies, glycan profiling has become indispensable for quality control, biomarker discovery, and therapeutic…
More Releases for NIU
NIU Health Opens New Location at 1441 Pali Highway in Honolulu
Image: https://www.globalnewslines.com/uploads/2025/07/1751546164.jpg
Walk-in patients of all ages in need of immediate health care like colds, flu and minor injuries are welcome
HONOLULU - July 3, 2025 - NIU Health today announced that it has moved its clinic to a new location at 1441 Pali Highway, Honolulu, HI 96813 [https://maps.app.goo.gl/22SwifYh719Uyh5v9], inside the YMCA building. The Grand Opening week will be July 10-11. The event will feature free blood pressure and glucose screenings from…
Honolulu Urgent Care Clinic by NIU Health: Go-To Destination for Immediate Medic …
NIU Health Urgent Care Clinic has established itself as a premier destination for individuals seeking immediate medical attention. As part of a broader effort to improve healthcare access in the region, this clinic provides a wide range of urgent care services designed to meet the needs of the community. With its focus on delivering high-quality, prompt medical care, NIU Health has become a trusted name in urgent care for both…
NIU Health Launches Premier Urgent Care in Waikiki, Meeting Local and Tourist Ne …
NIU Health's newest urgent care center in Waikiki offers a solution that meets these needs by providing immediate, high-quality care in one of the busiest areas of the island.
NIU Health has established itself as a leading provider of healthcare solutions in Hawaii, and with its new premier urgent care center in Waikiki, the company is set to make a significant impact on both locals and tourists alike. Waikiki, a popular…
Honolulu Urgent Care Clinic - NIU Health: Redefining Affordable Healthcare in th …
By focusing on affordable healthcare, they are addressing one of the most pressing concerns in the region: providing high-quality medical services without the financial burden that often accompanies them.
Honolulu, a city known for its breathtaking landscapes and rich cultural heritage, is now making waves in the healthcare sector, thanks to the Honolulu Urgent Care Clinic - NIU Health. In a time when healthcare costs continue to rise, the clinic is…
Affordable Healthcare at Its Best: Inside Honolulu Urgent Care Clinic - NIU Heal …
This clinic stands out as a beacon of hope for those seeking high-quality healthcare services without the exorbitant price tags typically associated with medical care.
In an era where healthcare costs seem to rise steadily, finding affordable healthcare options can be a daunting task. Fortunately, Honolulu Urgent Care Clinic - NIU Health is stepping up to the challenge with a groundbreaking approach that marries affordability with exceptional care. This clinic stands…
A New Standard for Affordable Healthcare: Honolulu Urgent Care Clinic - NIU Heal …
This clinic isn't just changing the game; it's setting a new standard for how healthcare should be delivered: with compassion, reliability, and affordability.
In the vibrant city of Honolulu, healthcare isn't just a service-it's a vital part of community well-being. Enter the Honolulu Urgent Care Clinic - NIU Health, a beacon of accessibility and affordability in local healthcare. This clinic isn't just changing the game; it's setting a new standard for…
